Bayer leads Robigo Series A to scale $10B crop protection platform
What's the deal? RobigoDealroom has a profile for this one. Try Dealroom →, a biotechnology company developing crop protection products from engineered microbes, has raised a Series A round led by Leaps by BayerDealroom has a profile for this one. Try Dealroom →. Illumina VenturesDealroom has a profile for this one. Try Dealroom →, SVG Thrive, Congruent VenturesDealroom has a profile for this one. Try Dealroom →, and Endeavor8Dealroom has a profile for this one. Try Dealroom → also participated. The amount was undisclosed.
What's the endgame? Robigo will accelerate the commercial launch of microbial biopesticides targeting fungal diseases in US soybeans and specialty crops. It also plans to expand its pipeline to additional soil-borne pathogens across broadacre agriculture, a market it estimates at $10bn.
How does it work? Robigo's ARGO platform uses synthetic biology and computational design to engineer living microbes that silence essential genes in plant pathogens. The company says its products need a one-time application, with the microbes producing active ingredients throughout the growing season. It aims to cut development timelines from the industry norm of three to five years to under 20 months.
Why BayerDealroom has a profile for this one. Try Dealroom →? Leaps by Bayer said its interest lies in the platform's scalability, not any single product. "They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens across broadacre crops," said Dr Juergen Eckhardt, head of Leaps by Bayer.
What's the pitch? Biological crop protection has long promised a sustainable alternative to chemicals, but many products have struggled with efficacy, consistency, and cost. Eckhardt said Robigo treats those as "an engineering and manufacturing challenge, not simply a product discovery challenge."
Why it matters: The company is first targeting costly diseases. Sudden Death Syndrome in soybeans costs US farmers an estimated $200m to $500m a year, while fusarium wilt hits lettuce and berry growers.
The signal: Founder and chief executive Dr Andee Wallace said growers "shouldn't have to choose between a product that works and one that's affordable or sustainable." With a strategic backer betting on the platform over any one product — and eyeing both proprietary sales and partnerships — Robigo reflects a shift toward engineering biologicals to compete head-on with conventional chemistries.
Read more: europesays.com
Image credit: Generated with Gemini
